BioLASCO Taiwan Co., Ltd. (TPEX:6662)
28.05
+1.45 (5.45%)
Nov 20, 2026, 12:53 PM CST
BioLASCO Taiwan Revenue
BioLASCO Taiwan had revenue of 71.74M TWD in the quarter ending September 30, 2026, with 13.47% growth. This brings the company's total for the last twelve months to 266.56M, down -3.81% year-over-year. In the year 2025, BioLASCO Taiwan had annual revenue of 262.66M, down -10.20%. That makes BioLASCO Taiwan the 38,295th largest company in the world by revenue and 1,995th in Taiwan.
Revenue (ttm)
266.56M
Revenue Growth
-3.81%
P/S Ratio
2.70
Revenue / Employee
2.93M
Employees
91
Market Cap
718.42M
Revenue by Geography
- Taiwan 282.59M 96.6%
- Others 9.91M 3.4%
Fiscal year ended Dec 31, 2024 See the full BioLASCO Taiwan breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.66M | -29.83M | -10.20% |
| Dec 31, 2024 | 292.50M | 27.78M | 10.49% |
| Dec 31, 2023 | 264.72M | 28.81M | 12.21% |
| Dec 31, 2022 | 235.91M | 8.33M | 3.66% |
| Dec 31, 2021 | 227.58M | -71.30M | -23.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 695.30M |
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 241.13M |
| NatureWise Biotech & Medicals | 174.62M |
| Lukas Biomedical | 170.01M |
| Holy Stone Healthcare | 47.51M |